# Breakthroughs in Alzheimer's Treatment: Safety and Innovation Newsy: Alzheimer’s News Weekly Published: 2026-09-07T13:30:00.527Z Source: https://newsyai.com/edition/1566d6fc-d4bc-416d-ab43-5323288ea768 Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- **Alzheimer’s Treatment Briefing: Safer Amyloid Options, Tau Gene Therapy Advances, and Better Symptom Relief** **Coverage period: September 1–September 7, 2026** Broad searches across news outlets, research databases, regulatory announcements, and trial registries highlighted several fresh developments in treatment research this week. The most relevant updates focus on an anti-amyloid antibody with an unusually clean safety profile, progress on a tau-lowering gene therapy, and new options for managing common symptoms like agitation and psychosis. Here are the key stories worth highlighting, ranked by potential impact on care. **1. PMN310 shows strong safety with zero brain swelling in early trial** **Overview** ProMIS Neurosciences shared interim results from a Phase 1b study of PMN310, an antibody designed to target only the most harmful forms of amyloid protein (the sticky clumps linked to Alzheimer’s). In 136 people with mild cognitive impairment or mild Alzheimer’s, none developed the type of brain swelling (called ARIA-E) that has been a concern with some other amyloid-clearing drugs—even among those carrying the higher-risk APOE4 gene. Overall side effects were low and mild, with some early signs that key disease markers in blood and spinal fluid were moving in a favorable direction.[[1]](https://www.psychiatrictimes.com/view/this-month-in-alzheimer-disease-july-s-pharmacology-and-research-developments) **Why this matters** Think of current amyloid drugs like a powerful vacuum that sometimes sucks up too much and causes side effects. PMN310 appears more like a precise filter that grabs only the worst debris without triggering swelling. If larger studies confirm this safety edge, it could make amyloid-targeting treatments accessible to more people, including those previously considered higher risk, and open doors for earlier or combination use. **2. VY1706 tau gene therapy shows durable effects and good safety in animal studies** **Overview** Voyager Therapeutics presented data on VY1706, an investigational gene therapy delivered by IV that aims to lower production of the tau protein (the tangled “wiring” inside brain cells). In nonhuman primates, a single dose cut tau-related activity by up to 75% in key brain areas for at least six months, with no signs of harm to the brain, nerves, or other organs. It also avoided common issues like liver irritation seen with some gene therapies. The FDA has cleared it for human testing; dosing in people with early Alzheimer’s is planned for the second half of 2026.[[1]](https://www.psychiatrictimes.com/view/this-month-in-alzheimer-disease-july-s-pharmacology-and-research-developments) **Why this matters** Tau changes track more closely with memory loss than amyloid alone. A one-time or infrequent treatment that dials down tau production inside the brain could complement existing approaches and potentially offer longer-lasting effects. Early safety signals in primates are encouraging for moving into human trials soon. **3. Oral cannabinoid combination reduces agitation in advanced dementia** **Overview** A Phase 2 trial of an oral mix of low-dose THC (2 mg) and CBD (100 mg) twice daily met its main goal in hospice-eligible people with Alzheimer’s or other dementias. Agitation scores improved noticeably within two weeks and kept improving through 12 weeks, with clinicians noting meaningful overall gains in most treated participants. Side effects were generally similar to placebo, though serious events occurred more often in the treatment group (none linked to the drug).[[1]](https://www.psychiatrictimes.com/view/this-month-in-alzheimer-disease-july-s-pharmacology-and-research-developments) **Why this matters** Agitation and distress affect many people in later stages and can be hard to manage without heavy side effects from current options. A simple oral cannabinoid blend that works relatively quickly could provide a gentler tool for comfort and quality of life, especially in advanced disease where disease-modifying therapies may have less impact. **4. Remlifanserin earns FDA Fast Track for Alzheimer’s-related psychosis** **Overview** Acadia Pharmaceuticals’ remlifanserin, a selective serotonin-receptor drug, received Fast Track designation for treating hallucinations and delusions in Alzheimer’s. It aims to calm overactive brain signaling without blocking dopamine (which can cause movement problems in older adults). A Phase 2 trial has finished enrolling, with results expected soon, and Phase 3 planning is underway.[[1]](https://www.psychiatrictimes.com/view/this-month-in-alzheimer-disease-july-s-pharmacology-and-research-developments) **Why this matters** Psychosis symptoms add significant stress for patients and families. A targeted option with a potentially better safety profile than some existing antipsychotics could improve daily life and reduce caregiver burden while researchers continue pursuing disease-slowing treatments. **What this means for care right now** - Approved treatments like lecanemab (Leqembi) and donanemab (Kisunla) remain options for eligible early-stage patients. - Symptom management (including emerging cannabinoid and targeted psychosis approaches) continues to be important alongside lifestyle factors such as heart health, exercise, sleep, and social engagement. - Clinical trial participation is still a key way to access emerging therapies—tools like online trial finders can help. - Talk with your doctor about the latest diagnostic options (blood tests, imaging) if cognitive changes are a concern. - Watch for more data from ongoing trials and upcoming conferences. **Sources** - Psychiatric Times summary of July 2026 Alzheimer’s pharmacology developments (published September 7, 2026). - Comprehensive web searches for Alzheimer’s news, trials, and announcements covering September 1–7, 2026 (conducted September 7, 2026). Research continues to expand options beyond single targets, with safety and symptom relief gaining ground alongside disease-modifying efforts.